Table 5.

Adverse events possibly or probably related to daptomycin^a

Age range (yr), sex	Wt (kg)	Underlying disease(s)b	DAP dosec	Adverse event	Onset of event/total DAP duration (days)	DAP DC	Outcome
31–50, M	141	CLCR of 30 to <50, OM, DM, HTN, GI disease (no statin)	6 mg/kg q24h	CPK increase	8/13	Yes	Resolved
51–65, F	71	CLCR of 30 to <50, HTN, COPD, anemia/hematologic disease, acute renal failure, solid organ cancer (no statin)	6 mg/kg q24h	CPK increase	7/11	Yes	Resolved
51–65, F	85	CLCR of <30	4 mg/kg q48h	Vaginal candidiasis	8/unknownd	No	Unknown
66–80, M	80	CLCR of <30 ml/min, IE, cardiac arrhythmias, HTN, COPD, renal disease	6 mg/kg q48h	Anemia	1/7	No	Resolved with residual effects

^aNone of the reported adverse events were serious. Abbreviations: CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CL_CR, creatinine clearance; CPK, creatine phosphokinase; DAP, daptomycin; DC, discontinued; GI, gastrointestinal; CV, cardiovascular; HTN, hypertension; PVD, peripheral vascular disease; IE, infective endocarditis; OM, osteomyelitis; DM, diabetes mellitus; M, male; F, female.

^bStart-of-treatment and end-of-treatment CL_CR groups did not change for the 4 patients during daptomycin therapy.

^cInitial and final daptomycin doses did not change for the 4 patients.

^dThe patient was monitored for 19 days after the onset of the adverse event; nothing about the vaginal candidiasis outcome was documented.